RA患者血浆和滑液中可溶性尿激酶受体的检测及其意义

目的探讨可溶性尿激酶受体(suPAR)在类风湿性关节炎(RA)病理损害中的作用。方法采用单克隆抗体酶免疫测定技术检测RA患者血浆及滑液中的suPAR含量,并与骨关节炎(OA)和正常对照组作比较。结果在正常人、OA和RA患者血浆中suPAR含量分别为(1. 81±1. 15), (8. 16±3. 73)和(36. 21±32. 74)ng/mL;OA和RA患者滑液中suPAR分别为(18.70±8. 82)和(47. 59 ±22. 86)ng/mL。RA患者滑液中suPAR水平显著高于血浆(P<0. 05),也明显高于OA滑液(P<0. 01),且RA患者滑液及血浆中suPAR水平呈显著性相关(r=0. 7906, 0. 8821) (P<0. 01)。结论RA患者血浆和关节液中可溶性尿激酶受体的水平均显著高于OA和对照组患者,提示:suPAR在RA的病理过程中发挥一定作用。

The Detection of Soluble Urokinase-type Plasminogen Activator Receptor in Plasma and Synovial Fluid of Patients with Rheumatoid Arthritis and its Significance

Objective To investigate the function of soluble urokinase-type plasminogen activator receptor(suPAR) in patients with rheumatoid arthritis(RA). Methods Levels of suPAR in plasma and synovial fluid (SF) in patients with RA were measured using specific ELISA, comparing with the OA and control group. Results The values of uPAR in plasma of normal, patients with OA, and RA were (1.81±1.15), (18.70±8.82) and (36.21 ±32.74) ng/mL, respectively. While suPAR in SF with OA and RA were (18.70±8.82) and (47.59 ±22.86)ng/mL. It is obviously that SF suPAR level in patients with RA was significantly higher than that of in plasma(P<0.05), which was also more than that of in patients with OA(P<0.01). There was a significant correlation between the concentration of suPAR in SF and plasma in patients with RA and OA ( r = 0. 7906 , 0.8821 respectively) (P<0.01). Conclusion Since the plasma and SF levels of suPAR in RA was significantly higher than that of in OA and control group, which indicates that suPAR may participate somehow in the pathology of RA.